Terns Pharmaceuticals (TERN)

• Market cap: $6.12B
• 1 day: 0.02%
• 5 days: 0.09%
• 1 month: 0.28%
• 3 months: 43.78%
• 6 months: 277.33%
• Year to date: 31.99%
• 1 year: 1,387.08%
• 5 years: 161.05%
• 10 years: 187.87%
• Sector: Healthcare
• Industry: Biotechnology

About: Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of chronic disease. The company's oncology asset is TERN-701, a novel, oral allosteric BCR-ABL1 inhibitor for CML currently in Phase 1/2 development. The company's legacy metabolic programs include TERN-501, a clinical-stage thyroid hormone receptor-Beta for MASH and/or obesity, and TERN-801, a glucose-dependent insulinotropic polypeptide receptor antagonist development candidate for obesity. The company is seeking strategic partners to advance the TERN-501 and TERN-801 programs.

Employees: 59